Abstract: A battery charging control device controls charging operations of rechargeable battery units, for which electrical energy is provided by an electrical energy source. The battery charging control device includes a charging control unit having an input connection capable of being coupled to the energy source for supplying an energy supply signal, and an output connection configuration with one or more parallel output connections for coupling a charger arrangement which comprises one or more chargers each having one or more charging ports for the rechargeable battery units. The charging control unit is configured to monitor the current provided by the energy source at the input connection and/or a current provided at a respective output connection and to enable the activation of a charging operation at a respective charging port.

Abstract: Some embodiments relate to systems for processing one or more computational workflows. In one embodiment, a description of a computational comprises a plurality of applications, in which applications are represented as nodes and edges connect the nodes indicate the flow of data elements between applications. A task execution module is configured to create and execute tasks. An application programming interface (API) is in communication with the task execution module and comprises a plurality of function calls for controlling at least one function of the task execution module. An API script includes instructions to the API to create and execute a plurality of tasks corresponding to the execution of the computational workflow for a plurality of samples. A graphical user interface (GUI) is in communication with the task execution module and configured to receive input from an end user to initiate execution of the API script.

Abstract: Some embodiments relate to systems for processing one or more computational workflows. In one embodiment, a description of a computational comprises a plurality of applications, in which applications are represented as nodes and edges connect the nodes indicate the flow of data elements between applications. A task execution module is configured to create and execute tasks. An application programming interface (API) is in communication with the task execution module and comprises a plurality of function calls for controlling at least one function of the task execution module. An API script includes instructions to the API to create and execute a plurality of tasks corresponding to the execution of the computational workflow for a plurality of samples. A graphical user interface (GUI) is in communication with the task execution module and configured to receive input from an end user to initiate execution of the API script.

Abstract: The present invention relates to a catalytic composition comprising at least 7 different elements selected from the group consisting of the elements defined by the intersection of the second to the sixth period and the first to the sixteenth group of the periodic table of the elements, whereby technetium is excluded, and a matrix component. A method for use of the catalytic composition is also provided.

Abstract: Some embodiments relate to systems for processing one or more computational workflows. In one embodiment, a description of a computational comprises a plurality of applications, in which applications are represented as nodes and edges connect the nodes indicate the flow of data elements between applications. A task execution module is configured to create and execute tasks. An application programming interface (API) is in communication with the task execution module and comprises a plurality of function calls for controlling at least one function of the task execution module. An API script includes instructions to the API to create and execute a plurality of tasks corresponding to the execution of the computational workflow for a plurality of samples. A graphical user interface (GUI) is in communication with the task execution module and configured to receive input from an end user to initiate execution of the API script.

Abstract: The present invention concerns a method for production of an active ingredient of a drug or diagnostic agent, in which (a) MDCK cells are infected with a virus; and (b) the MDCK cells are cultured in suspension culture on a commercial scale under conditions that permit multiplication of the viruses; in which culturing occurs in a volume of at least 30 L. The invention also concerns a method for production of a drug or diagnostic agent in which an active ingredient is produced according to the above method and mixed with an appropriate adjuvant, auxiliary, buffer, diluent or drug carrier.

Abstract: Some embodiments relate to systems for processing one or more computational workflows. In one embodiment, a description of a computational comprises a plurality of applications, in which applications are represented as nodes and edges connect the nodes indicate the flow of data elements between applications. A task execution module is configured to create and execute tasks. An application programming interface (API) is in communication with the task execution module and comprises a plurality of function calls for controlling at least one function of the task execution module. An API script includes instructions to the API to create and execute a plurality of tasks corresponding to the execution of the computational workflow for a plurality of samples. A graphical user interface (GUI) is in communication with the task execution module and configured to receive input from an end user to initiate execution of the API script.

Abstract: The present invention relates to a new route of synthesis for obtaining Opicapone ((4Z)-4-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-2H-1,2,4-oxadia-zol-5-ylidene]-2-hydroxy-6-nitrocyclohexa-2,5-dien-1-one), new intermediates in the reaction path and the new substance 2,5-dichloro-N-hydroxy-4,6-dimethylpyridine-3-carboximidoyl chloride.

Abstract: The invention relates to a skin substitute for investigating the behavior of cosmetic and pharmaceutical compositions to be applied topically, where the skin substitute is a three-dimensionally crosslinked polyacrylamide matrix and water and at least one polypeptide is bonded in

Abstract: The present invention concerns a method for production of an active ingredient of a drug or diagnostic agent, in which (a) MDCK cells are infected with a virus; and (b) the MDCK cells are cultured in suspension culture on a commercial scale under conditions that permit multiplication of the viruses; in which culturing occurs in a volume of at least 30 L. The invention also concerns a method for production of a drug or diagnostic agent in which an active ingredient is produced according to the above method and mixed with an appropriate adjuvant, auxiliary, buffer, diluent or drug carrier.

Abstract: The present invention concerns methods for multiplication of viruses in cell culture in which cells are infected with a virus and after infection the cells are cultured in cell culture under conditions that permit multiplication of the viruses and at the same time targeted additional, at least two-fold, multiplication of the cells. The invention also concerns the use of the viruses so obtained or proteins expressed by them for production of drugs and diagnostic agents.